Jeremy B. Green MD: A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI) for the Treatment of Dynamic Forehead Lines (FHL) Following Glabellar Line (GL) Injections

Your comment